



an Open Access Journal by MDPI

## Targets, Tracers and Translation, Part 2 - New Horizons in Radiopharmaceutical Development

Guest Editor:

### Prof. Dr. Gerald Reischl

1. Department of Preclinical Imaging and Radiopharmacy, University of Tübingen, Tübingen, Germany  
2. Cluster of Excellence iFIT (EXC 2180) "Image Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, Germany

Deadline for manuscript submissions:

**closed (31 December 2021)**

### Message from the Guest Editor

Dear Colleagues,

Two years have passed since our first Special Issue on "Targets, Tracers and Translation". In the meantime, the journal was indexed by SCIE with an impressive IF of 4.286 for 2019. As the first Special Issue was a remarkable success, it has now been decided that the right time has arrived to open a Part 2.

With this Special Issue, we want to illustrate and highlight the variety in recent radiopharmaceutical developments and the new horizons that are opened toward a broad spectrum of applications. The final goal of these developments, of course, the successful translation into the clinics and into nuclear medicine practice, should always be the focus.

We cordially invite you to participate in this Special Issue, "Targets, Tracers and Translation, Part 2—New Horizons in Radiopharmaceutical Development" and are excited to receive your latest successful results and share them with the community. In addition to original works, reviews are very welcome, as well.



[mdpi.com/si/68217](https://mdpi.com/si/68217)

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Pharmaceutical Science*)

## Contact Us

*Pharmaceuticals* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceuticals](http://mdpi.com/journal/pharmaceuticals)  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)